“Our primary focus for the Renaissance is the ambulatory surgery center, or ASCs, a market segment that we believe will take advantage of the system’s value pricing,” said Mr. Hadomi. The company will continue to target the inpatient hospital market with its next-generation robotic technology, Mazor X, along with innovation development and marketing partner Medtronic.
The company has an ambitious outlook on the market.
“In the U.S., we believe there are approximately 1,000 ASCs that would benefit from using the Renaissance system,” said Mr. Hadomi. “At the same time, we don’t believe this will cannibalize any Mazor X system sales due to the case volume and system costs.”
More articles on spine surgery:
Inpatient vs. outpatient spinal fusions: 5 findings on complication rates
15+ spine surgeons performing total disc replacement in ASCs
Top 4 trends in global spine surgery market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
